MedAI Verdict

AI Radiology

Editorial illustration: a chest radiograph alongside a magnifying glass highlighting flagged regions in blue.

Clarius vs ScreenPoint Transpara

All comparisons
53/ 100

Clarius

Solid choice
56/ 100

ScreenPoint Transpara

Solid choice

ScreenPoint's Transpara supports cancer detection on 2D FFDM and 3D DBT mammograms, and breast screening services reading mammograms are its customers. openFDA lists eight Transpara decisions, the latest in August 2026. The company raised EUR 13.6M in April 2026.

The vendor says Transpara was the software in MASAI, a randomized mammography screening trial in Sweden. The 2026 Lancet interval-cancer analysis of MASAI, academic work from Lund University, reported sensitivity of 80.5% with AI support against 73.8% for standard double reading, at 98.5% specificity, across more than 105,000 women. The vendor separately claims a 29% cancer detection increase and a 44% workload reduction.

The vendor says Clarius Prostate AI returns TRUS and TAUS prostate volume, and openFDA holds it as K243853. That suits a urology practice. Prostate volume and breast cancer detection are different clinical tasks on different devices, so a urology practice and a breast screening service buy separately.

Radiology · Reviewed November 2, 2026

On this page
Clarius logo

Clarius

by Clarius Mobile Health

Wireless handheld ultrasound scanners with FDA-cleared onboard AI tools for bladder, prostate, OB and cardiac measurement.

ScreenPoint Transpara logo

ScreenPoint Transpara

by ScreenPoint Medical

Transpara Breast AI: cancer detection support, density and risk tools for 2D and 3D mammograms.

When to pick each one

Clarius

  • Vendor says Prostate AI returns TRUS and TAUS volume
  • FDA decision K243853 covers Clarius Prostate AI
Read the full Clarius review

ScreenPoint Transpara

  • Works with 2D FFDM and 3D DBT mammography systems
  • Eight Transpara 510(k) decisions, latest August 2026
  • Vendor says Transpara was the software in MASAI
Read the full ScreenPoint Transpara review

Score

Each row shows points earned of points available under the published rubric.

Clarius

53of 100Solid choice

ScreenPoint Transpara

56of 100Solid choice
Score by dimension for Clarius and ScreenPoint Transpara
DimensionClariusScreenPoint TransparaDifference
FDA clearance18 / 1818 / 180
HIPAA / SOC2 / BAA0 / 100 / 100
EHR integrations (count)0 / 4.20 / 4.20
Top-3 EHR coverage (Epic / Oracle / Athena)0 / 2.40 / 2.40
Peer-reviewed papers12.7 / 18.212.7 / 18.20
RCT / meta-analysis / systematic review7.8 / 7.87.8 / 7.80
Funding & adoption signal3 / 126 / 12-3
Pricing transparency2.5 / 52.5 / 50
Years in market0 / 60 / 60

Scroll horizontally to see every column.

How scores are computed

Pricing

Clarius

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price verified.

ScreenPoint Transpara

TierMonthlyAnnualNotes
EnterpriseNot statedNot statedNo public price. Virtual demo and contact only.

Evidence

Compliance and integrations

Documented from each vendor’s own pages.

SpecClariusScreenPoint Transpara
Free tierNo / unverifiedNo / unverified
HIPAANo / unverifiedNo / unverified
SOC 2 Type IINo / unverifiedNo / unverified
EHR integrationsNot statedNot stated
FoundedNot statedNot stated
HQNot statedNL

Scroll horizontally to see both columns.

Common questions

Open the full radiology comparison

Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.

See all radiology